Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals and Financings

Set Alert for Deals

M&A Analysis: October Notches 30 Deals In Big M&A Boom

The medtech M&A deal count soared in October with a total of 30 deals announced and closed in the month. It was an especially busy month for the orthopedics sector, with a number of high profile deals inked.

M & A Deals Commercial
Advertisement

Latest From Deals

China's MicroPort Bags A Bargain In LivaNova's CRM Unit

Some two months after disclosing its intention to cast off its struggling cardiac rhythm management unit, LivaNova has struck a deal to sell the business to its Chinese joint venture partner MicroPort Scientific at a discounted price of $190m.

Cardiology Deals

Pacts In Medtech, Sept/Oct 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in September and October 2017.

Pacts in Medtech Deals

VC Deals Analysis: Only Way Is Up As October Puts 2017 Ahead

Total takings from October's venture financing deals may not have been the highest, but the $295m raised by the 20-plus transactions last month is enough for 2017 to trump 2016 in total deal value – with more room to widen the gap.

StartUps and SMEs Financing

Novartis Confirms Rumors With $3.9bn Deal For AAA's Nuclear Med Biz

Recent speculation about Novartis' interest in nuclear medicine specialist AAA has been confirmed, after the pharma giant inked a deal worth $3.9bn to acquire the French firm. Integrating AAA would add to Novartis' expertise in diseases associated with neuroendocrine tumors and bring it a new technology platform for treating cancer.

M & A Cancer

Stryker's Deal For Spine Device Maker Vexim Rounds Up Ortho M&A Trilogy

It's been a busy week for ortho M&A activity, with three key sector players cutting deals. Smith & Nephew's agreement to buy Rotation Medical kick-started the week, then two more deals followed in succession, with Exactech announcing it was to be acquired by private equity firm TPG Capital and Stryker saying it will acquire a majority control of Vexim, a French spinal device maker.

Orthopedics M & A

Smith & Nephew To Acquire Regenerative Shoulder-Tech Firm

Th UK firm is buying Rotation Medical and its regeneration technology for shoulder rotator cuff repair for $125m, plus milestones, to grow its sports-medicine portfolio. The deal comes amid rumors that Smith & Nephew could be positioning itself to be acquired.

M & A Orthopedics

M&A Analysis: Steady Goes September

Medtech M&A deal making has resumed the pace of activity seen before the brief surge in the summer. 17 M&A deals were announced and recorded on the Medtech Insight M&A deal tracker, one more than the previous month but included a few billion dollar transactions.

M & A Deals

Angle's Maiden M&A Fills Gaps In Liquid Biopsy Solution

By acquiring Axela Inc, liquid biopsy specialist Angle PLC will now be able to pair the Canadian firm's gene expression measurement technology with its Parsortix circulating tumor cell harvesting system. Angle will finance this transaction with the proceeds it expects to raise from a proposed £12.2m share placement.

Cancer In Vitro Diagnostics

VC Deals Analysis: Quarter-Billion Round Hikes September Takings To Five-Year High

September benefitted from two nine-figure venture financing rounds, including a $250m round by consumer genetic test service provider 23andme. These bumper deals significantly boost the total takings in 2017 so far to the extent that the year looks likely to beat 2016.

Deals Financing
See All
UsernamePublicRestriction

Register